Results 111 to 120 of about 6,088 (209)

Artificial intelligence empowers targeted protein degradation: Core technological innovations, multi‐scenario applications, and translational prospects

open access: yesSmart Molecules, EarlyView.
AI is transforming TPD by improving the design, prediction, and optimization of degraders such as PROTACs, molecular glues, and LYTACs. This review summarizes key AI‐driven advances, highlights applications across drug discovery stages, and discusses remaining challenges and future directions for accelerating the development of therapies against ...
Shuanglin Qin   +10 more
wiley   +1 more source

Thrombocytosis and tumour distribution predict outcome in dogs with hepatocellular carcinoma: A multi‐institutional retrospective analysis

open access: yesVeterinary Record, EarlyView.
Abstract Background Hepatocellular carcinoma (HCC) is the most common canine hepatobiliary tumour. This study aimed to determine which criteria influenced outcome of HCC in a modern population of dogs across eight institutions. Methods The medical records of 106 dogs with HCC were retrospectively reviewed.
Emily A. Janik   +2 more
wiley   +1 more source

Epiphora: A Structured Diagnostic Approach for the Otolaryngologist

open access: yesWorld Journal of Otorhinolaryngology - Head and Neck Surgery, EarlyView.
ABSTRACT Introduction Epiphora, or excessive tearing, has historically been predominantly managed by ophthalmologists. However, as there is substantial overlap between ophthalmic and otolaryngologic anatomy and pathology that may contribute to epiphora, patients with this symptom often present to otolaryngologists as well.
Luke M. O'Neil   +7 more
wiley   +1 more source

Review on enhancing clinical decision support system using machine learning

open access: yesCAAI Transactions on Intelligence Technology, EarlyView.
Abstract Clinical decision‐making is a complex patient‐centred process. For an informed clinical decision, the input data is very thorough ranging from detailed family history, environmental history, social history, health‐risk assessments, and prior relevant medical cases.
Anum Masood   +4 more
wiley   +1 more source

Pancreatic Panniculitis as the First Presentation of Pancreatic Adenocarcinoma

open access: yes
JEADV Clinical Practice, EarlyView.
Claudine Howard‐James   +2 more
wiley   +1 more source

SENIOR‐IPI: An easily applicable prognostic index for first‐line large B‐cell lymphomas patients >80 years treated with curative intent

open access: yesBritish Journal of Haematology, EarlyView.
Summary Using LYmphoma Study Association clinical trials combining 438 first‐line large B‐cell lymphomas (LBCL) patients >80 years old, we defined SENIOR‐IPI, an easily applicable prognostic index for this elderly population treated with an anti‐CD20‐miniCHOP (cyclophosphamide, doxorubicin, vincristine and prednisone)‐based regimen.
Sydney Dubois   +8 more
wiley   +1 more source

Unusual manifestation of diffuse large B-cell lymphoma [PDF]

open access: yesPolish Archives of Internal Medicine, 2020
Izabela, Rubisz   +3 more
openaire   +3 more sources

Predicted microbiome‐associated metabolic pathways are linked to immune checkpoint modulation in chronic lymphocytic leukaemia

open access: yesBritish Journal of Haematology, EarlyView.
Summary Microbial metabolites are key regulators of host immunity, yet their functional impact in chronic lymphocytic leukaemia (CLL) remains unclear. Following up on our earlier observations of microbiome dysbiosis in CLL, we performed predictive metabolic profiling based on 16S ribosomal RNA (rRNA) sequencing of oral and stool samples collected from ...
Monika Szelest   +15 more
wiley   +1 more source

Primary Diffuse Large Cell Lymphoma of the Bladder: Case Report and Literature Review

open access: yesMiddle East Journal of Cancer, 2017
Most bladder tumors are epithelial in origin. Nonepithelial cancers are rarely located in the bladder. Sarcomas are the most common malignancies among nonepithelial cancers. Primary bladder lymphoma is rare and mostly low grade. Here, we have reported
Mansour Ansari   +8 more
doaj  

SAKK 35/14 randomized trial of rituximab with or without ibrutinib for patients with untreated follicular lymphoma

open access: yesBritish Journal of Haematology, EarlyView.
Summary The randomized phase II SAKK 35/14 trial, conducted by the Swiss Group for Clinical Cancer Research (SAKK) and the Nordic Lymphoma Group (NLG), compared efficacy and safety of rituximab (375 mg/m2 intravenously for 4 weeks followed by maintenance every 2 months for 24 months) plus placebo (arm A) versus the same schedule of rituximab plus ...
Maria Cristina Pirosa   +25 more
wiley   +1 more source

Home - About - Disclaimer - Privacy